As a global leading contract development and manufacturing organization (CDMO) for cell and gene therapy products, Minaris Regenerative Medicine has been offering our clients high value clinical and commercial manufacturing services, development solutions, and technologies for more than 20 years.
As a global company with facilities in the U.S., Germany, and Japan, we will be shifting to a model of regional operational leadership beginning October 1, 2021. The three regional Chief Operating Officers will collaborate on a Global Functional team. Please read our press release to learn more about those appointed.
At Minaris, we are experts for development, clinical, and commercial manufacturing of cell and gene therapies. Together with our partners, we have a vision of creating future cell therapy miracles. This allows us to constantly push the boundaries of medicine to serve patients in need. Watch our video to learn more about how we achieve this.
Our manufacturing development services help you design efficient and robust manufacturing processes for your cell and gene therapy.
We offer a comprehensive manufacturing experience that is fully compliant with the relevant regional regulatory requirements of our global facilities.